Stoke Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Stoke Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.42M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $36.56M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $8.78M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $12.41M | Mar 25, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.89M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($88.98M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($104.70M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($101.07M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($85.81M) | Mar 6, 2023 |
| FY2020 | Dec 31, 2020 | ($14.56M) | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | ($13.68M) | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | ($12.96M) | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($11.04M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | ($10.16M) | Mar 9, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.59M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($101.37M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($114.77M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($104.36M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($86.07M) | Mar 6, 2023 |
| FY2020 | Dec 31, 2020 | ($14.59M) | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | ($13.71M) | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | ($13.01M) | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($11.74M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | ($11.07M) | Mar 9, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.92M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $89.13M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $82.23M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $77.84M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $54.17M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $32.20M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $23.76M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $8.37M | Mar 23, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.09M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $48.79M | Mar 16, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.59M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($86.85M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($81.07M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($31.87M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($66.91M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($42.22M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($31.06M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($10.96M) | Mar 23, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $670.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $203.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.62M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.96M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.20M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $1.05M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.64M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $935.0K | Mar 23, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.43M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $271.56M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $228.34M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $256.07M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $238.87M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $297.93M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $228.75M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $107.54M | Mar 23, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.98M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $42.53M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $68.78M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $71.22M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $21.09M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $11.85M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $4.32M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.47M | Mar 23, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $352.46M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $229.02M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $159.57M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $184.85M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $217.78M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $286.08M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $224.43M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $105.07M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | ($1.29M) | Mar 23, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($497.72M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($490.83M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($401.85M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($297.15M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($196.08M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($110.28M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($58.04M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($25.71M) | Mar 23, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.22M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $127.98M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $191.44M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $113.56M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $144.90M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $287.31M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $222.47M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $105.40M | Mar 23, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 6, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 6, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 58.92M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 54.03M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 45.92M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 39.44M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 36.90M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 36.58M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 32.86M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 727,413 | Mar 23, 2020 |